The augment of LC3-II revealed that the administration of gefitinib induced autophagic flux and increased autophagic activity in NSCLC cells harboring EGFR T790M mutation (supplemental Fig. S3C). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.